With monogenetic neurodevelopmental disorders similar to autism serving as starting points for several drug discovery programs, smaller biotechs are now joining big pharma in pursuing therapies to tackle this perplexing condition. Sarah Webb reports.
This is a preview of subscription content, log in via an institution to check access.
References
Pinto, D. et al. Nature 466, 368–372 (2010).
Berkel, S. et al. Nat. Genet. 42, 489–491 (2010).
Guy, J. et al. Science 315, 1143–1147 (2007).
Dölen, G. et al. Neuron 56, 955–962 (2007).
Andari, E. et al. Proc. Natl. Acad. Sci. USA 107, 4389–4394 (2010).
Ring, R.H. et al. Neuropharmacology 58, 69–77 (2010).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Webb, S. Drugmakers dance with autism. Nat Biotechnol 28, 772–774 (2010). https://doi.org/10.1038/nbt0810-772
Issue Date:
DOI: https://doi.org/10.1038/nbt0810-772
- Springer Nature America, Inc.
This article is cited by
-
Social Skills Deficits in Autism Spectrum Disorder: Potential Biological Origins and Progress in Developing Therapeutic Agents
CNS Drugs (2018)
-
Rates and Predictors of Adherence to Psychotropic Medications in Children with Autism Spectrum Disorders
Journal of Autism and Developmental Disorders (2014)
-
Parents’ Perspectives on Participating in Genetic Research in Autism
Journal of Autism and Developmental Disorders (2013)